Table 2.

Ongoing clinical trials targeting epigenetic regulators in non-small-cell lung cancer (NSCLC) (as of March 11, 2020)

NCT number	Drug(s)	Epigenetic target
NCT01928576	azacitidine + entinostat + nivolumab	DNMT, HDAC
NCT03233724	decitabine + tetrahydrouridine + pembrolizumab	DNMT, HDAC
NCT03220477	guadecitabine + mocetinostat + pembro	DNMT, HDAC
NCT02664181	nivolumab + decitabine + tetrahydrouridine	DNMT
NCT02250326	nab-paclitaxel + azacitidine	DNMT
NCT02546986	azacitidine + pembrolizumab	DNMT
NCT02959437	azacitidine + pembrolizumab + epacadostat	DNMT
NCT02635061	ACY-241 + nivolumab	HDAC6
NCT02805660	mocetinostat + durvalumab	HDAC
NCT02437136	entinostat + pembro	HDAC
NCT02638090	pembrolizumab + vorinostat	HDAC
NCT02954991	mocetinostat + nivolumab	HDAC
NCT03590054	abexinostat + pembrolizumab	HDAC
NCT02718066	HBI-8000 + nivolumab	HDAC